Influenza vaccine effectiveness against influenza-associated hospitalizations and emergency department or urgent care encounters among children and adults — VISION, United States, 2024–25 season
Clicks: 2
ID: 323643
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
0.3
/100
2 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #119 of 208 articles by views in Open forum infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 208 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background The 2024–25 influenza season was the most severe in the United States (US) since 2017–18, with co-circulation of both influenza A virus subtypes (H1N1 and H3N2). Influenza vaccine effectiveness (VE) has varied by season, setting, and patient characteristics. Methods Using electronic healthcare encounter data from seven VISION sites in eight US states, we evaluated influenza vaccine effectiveness (VE) against influenza-associated hospitalizations and emergency department or urgent care (ED/UC) encounters from October 2024–April 2025 among children aged 6 months–17 years and adults aged ≥18 years. Using a test-negative, case-control design, we compared the odds of influenza vaccination between acute respiratory illness encounters with a positive (cases) versus negative (controls) test for influenza by molecular assay, adjusting for confounders. Results Analyses included 108,618 encounters (5,764 hospitalizations and 102,854 ED/UC encounters) among children and 309,483 encounters (76,072 hospitalizations and 233,411 ED/UC encounters) among adults. Among children across care settings, 17.0% (6,097/35,765) of cases versus 29.4% (21,449/72,853) of controls were vaccinated. Among adults, 28.2% (21,832/77,477) of cases versus 44.2% (102,560/232,006) of controls were vaccinated. VE was 51% (95% confidence interval [95% CI]: 41–60%) against influenza-associated hospitalizations and 54% (95% CI: 52–55%) against influenza-associated ED/UC encounters among children. VE was 43% (95% CI: 41–46%) against influenza-associated hospitalizations and 49% (95% CI: 47–50%) against influenza-associated ED/UC encounters among adults. Conclusions Influenza vaccination provided protection against influenza-associated hospitalizations and ED/UC encounters among children and adults in the US during the severe 2024–25 influenza season. These findings support influenza vaccination as an important tool to reduce influenza.
| Reference Key |
openalex_W7172408776
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Jennifer DeCuir, Emily Reeves, Zachary A. Weber, Duck‐Hye Yang, Stephanie A. Irving, Sara Y. Tartof, Nicola P. Klein, Shaun J. Grannis, Toan C. Ong, Sarah W. Ball, Malini B. DeSilva, Kristin Dascomb, Allison L. Naleway, Pradeep Koppolu, S Bianca Salas, Lina S. Sy, Bruno Lewin, Richard Contreras, Ousseny Zerbo, John Hansen, Lawrence Block, Karen B Jacobson, Brian E. Dixon, Colin Rogerson, Thomas J. Duszynski, William F. Fadel, Michelle A. Barron, David Mayer, Catia Chavez, Adam Yates, Lindsey Kirshner, Charlene E McEvoy, Omobosola Akinsete, Inih Essien, Tamara Sheffield, Daniel Bride, Julie Arndorfer, Josh V Otterloo, Karthik Natarajan, Caitlin Ray, Amanda B. Payne, Katherine Adams, Brendan Flannery, Shikha Garg |
| Journal | Open forum infectious diseases |
| Year | 2026 |
| DOI |
10.1093/ofid/ofag473
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.